Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage ...
Eli Lilly said on Wednesday its experimental pill, orforglipron, helped reduce blood sugar levels in two late-stage trials.
Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come ...
Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...
Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work ...
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of ...
Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...
Lilly is looking to build four pharmaceutical plants across the country. Two announcements are in the works.
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly, STAT News ...
Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ...
YouTuber-turned-TV personality Lilly Singh is ready to tack "PhD" onto her email signature after receiving an honorary doctor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback